Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis.

ABSTRACT:

Background

The ryanodine receptors (RYRs) have been implicated in many muscular, cardiac and neurological diseases. However, there are almost no studies so far focusing on RYR genetic alterations and its roles in cancer, especially in non-small cell lung cancer (NSCLC).

Methods

The whole-exome sequencing (WES) data, demographic and clinical data of 1,052 NSCLC patients was downloaded from The Cancer Genome Atlas (TCGA) database and analyzed using the corresponding packages of the R software. Mutational profile was established and its correlation with tumor mutational burden (TMB), prognosis, age and smoking status was analyzed and compared.

Results

RYR mutations were found in 502 NSCLC patients, in which mutations of RYR1, RYR2 and <

SUBMITTER: Wang Y 

PROVIDER: S-EPMC9372243 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature